The FDA has granted breakthrough therapy designation status to Genentech’s rituximab (Rituxan) for pemphigus vulgaris (PV), a rare, serious, and life-threatening autoimmune disease with limited treatment options.
The designation is intended to expedite the development and review of medications with early evidence of potential clinical benefit in serious diseases and to help ensure that patients get access to these medications as soon as possible. Patients diagnosed with PV are currently being enrolled for a phase 3 trial of rituximab.
Rituximab is currently approved for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
The breakthrough status came following a review of data from a Roche-supported randomized trial conducted in France that evaluated rituximab plus oral corticosteroid treatment compared with corticosteroid as a first-line treatment in patients with moderate to severe pemphigus. (Roche markets rituximab outside the United States and Japan.) The study, which was published in The Lancet, showed that Rituxan may provide substantial improvement in disease remission rates and successful tapering and/or cessation of corticosteroid therapy.
Meanwhile, there’s been progress with developing a biosimilar for rituximab. The European Medicines Agency (EMA) is expected to soon grant approval for Celltrion’s rituximab biosimilar (Truxima). The EMA’s Committee for Medicinal Product for Human Use announced on December 16, 2016, that it had recommended granting marketing approval for rituximab biosimilar. European oncologists expect the arrival of a rituximab biosimilar to slash costs and expand patient access to the expensive oncology treatment. Europe would be the first big market for rituximab biosimilars because a US approval of biosimilar rituximab is probably farther in the future.
The rituximab biosimilar has already penetrated the Asian market—it was approved in 2016 in South Korea, covering all indications of the reference drug. In the United States, Celltrion is collaborating with Teva, which will commercialize the biosimilar if approved here.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.